title: Aminophylline treatment in meconium-induced acute lung injury in a rabbit model.
abstract: Administration of methylxanthines may diminish meconium-induced acute lung injury. Meconium-instilled rabbits intravenously received aminophylline (2.0 mg/kg) at two doses 0.5 h and 2.5 h after meconium instillation or were left without treatment, and were oxygen-ventilated for additional 5 h. At the end of experiment, lungs and trachea were excised. Within 5 h after the first dose of treatment, aminophylline significantly improved gas exchange and decreased right-to-left pulmonary shunts, central venous pressure, and ventilatory pressures. Moreover, aminophylline reduced meconium-induced lung edema formation, airway hyperreactivity to histamine, count of neutrophils in bronchoalveolar lavage fluid associated with higher total white blood cells and neutrophils in the blood, and diminished oxidative modifications of proteins and lipids in lung tissue compared with the non-treated meconium-instilled group. In a rabbit model of the meconium aspiration syndrome, aminophylline treatment enhanced pulmonary functions and alleviated oxidative injury and changes in airway reactivity related to lung inflammation.
authors.affiliation: Department of Physiology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia. mokra@jfmed.uniba.sk
authors.forename: D
authors.initials: D
authors.lastname: Mokra
authors.forename: J
authors.initials: J
authors.lastname: Mokry
authors.forename: Z
authors.initials: Z
authors.lastname: Tatarkova
authors.forename: B
authors.initials: B
authors.lastname: Redfors
authors.forename: M
authors.initials: M
authors.lastname: Petraskova
authors.forename: A
authors.initials: A
authors.lastname: Calkovska
mesh_terms: D000628:Aminophylline / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001985:Bronchial Provocation Tests; D016084:Bronchoconstriction / Q000187:drug effects; D016085:Bronchoconstrictor Agents / Q000008:administration & dosage; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002496:Central Venous Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D006632:Histamine / Q000008:administration & dosage; D006801:Humans; D007231:Infant, Newborn; D007275:Injections, Intravenous; D015227:Lipid Peroxidation / Q000187:drug effects; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D008471:Meconium Aspiration Syndrome / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D020556:Neutrophil Infiltration / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D011015:Pneumonia, Aspiration / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D050050:Protein Carbonylation / Q000187:drug effects; D011652:Pulmonary Circulation / Q000187:drug effects; D011654:Pulmonary Edema / Q000517:prevention & control; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D012123:Pulmonary Ventilation / Q000187:drug effects; D011817:Rabbits
chemical_list: D000893:Anti-Inflammatory Agents; D016085:Bronchoconstrictor Agents; D001993:Bronchodilator Agents; D000628:Aminophylline; D006632:Histamine